Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING
NCT ID: NCT02645968
Last Updated: 2020-12-07
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
600 participants
Study Classification
OBSERVATIONAL
Study Start Date
2014-05-31
Study Completion Date
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to collect valid data from all forms of health care on the incidence, prevalence, the regional distribution, characteristics, management and outcomes of different ILDs under clinical practice conditions.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interstitial lung diseases (ILD) are a heterogeneous group of more than 200 entities that can be idiopathic or as a result of other diseases and/or treatments. All forms of ILD are considered to be seldom or very seldom (and most of them are so-called "orphan" diseases), in their entirety they seem to represent an epidemiological burden, which should not be underestimated, e.g. as "normal" symptoms of the elderly.
The knowledge about the epidemiology of ILDs is very limited, in general and in Germany in particular. For Germany no current, valid and comprehensive population-based data on ILDs exist because no appropriate ILD classification was available for a long time. The epidemiological data, which were collected before the introduction of the current classification of ILD according to the ATS/ERS consensus and before HRCT was considered the diagnostic gold standard, are not very reliable. Furthermore systemic investigations relating to the development of an ILD of risk groups, such as patients undergoing radio- or chemotherapy or patients with connective tissue disease, are restricted.
Thus, only little is known about costs associated with ILDs. Idiopathic Pulmonary Fibrosis (IPF), as one of the disease entities, was shown to be associated with high healthcare utilization and costs in England and the USA, as in many cases lung transplantation is the only therapeutic option and also new pharmaceutical treatments are costly. But there is a lack of data on healthcare utilization and financial consequences of other ILD than IPF in Germany. Therefore, this registry will provide an important database for health economics and health services research questions.
Against this background, this multi-centre, non interventional prospective observational disease and outcomes registry for ILD aims to collect valid data from all forms of health care on the incidence, prevalence, the regional distribution, characteristics, management and outcomes of different ILDs under clinical practice conditions. In detail, demographic data such as gender, age, country of birth, place of residence; disease related data such as subtype of ILD, treatment center, diagnostic procedures (e.g. HRCT, lung biopsy, pulmonary function tests); risk factors (e.g. smoking status, profession, familial ILD); co-morbidities; ILD management as analysed by the kind and frequency of pharmacological and non-pharmacological therapies; outcome; and consumption of resources will be recorded. Therefore, this registry will allow obtaining a comprehensive and current epidemiologic report for ILDs in Germany and can be particularly helpful in uncovering correlations between risk exposure and disease development.
This study, with up to 100 sites, initially focused on the federal states Baden-Wuerttemberg and Hesse, is planned for a minimum of 5 years and 600 patients should be enrolled as part of the study a screening/baseline visit, on which the Informed Consent Form will be signed, and every 6 months regularly updates/phone contacts will be performed.
Following quality procedures are applicable for this registry:
* Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.
* Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
* Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms, or interactive voice response systems).
* Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.
* Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.
* Plan for missing data to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results
* Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.
The knowledge about the epidemiology of ILDs is very limited, in general and in Germany in particular. For Germany no current, valid and comprehensive population-based data on ILDs exist because no appropriate ILD classification was available for a long time. The epidemiological data, which were collected before the introduction of the current classification of ILD according to the ATS/ERS consensus and before HRCT was considered the diagnostic gold standard, are not very reliable. Furthermore systemic investigations relating to the development of an ILD of risk groups, such as patients undergoing radio- or chemotherapy or patients with connective tissue disease, are restricted.
Thus, only little is known about costs associated with ILDs. Idiopathic Pulmonary Fibrosis (IPF), as one of the disease entities, was shown to be associated with high healthcare utilization and costs in England and the USA, as in many cases lung transplantation is the only therapeutic option and also new pharmaceutical treatments are costly. But there is a lack of data on healthcare utilization and financial consequences of other ILD than IPF in Germany. Therefore, this registry will provide an important database for health economics and health services research questions.
Against this background, this multi-centre, non interventional prospective observational disease and outcomes registry for ILD aims to collect valid data from all forms of health care on the incidence, prevalence, the regional distribution, characteristics, management and outcomes of different ILDs under clinical practice conditions. In detail, demographic data such as gender, age, country of birth, place of residence; disease related data such as subtype of ILD, treatment center, diagnostic procedures (e.g. HRCT, lung biopsy, pulmonary function tests); risk factors (e.g. smoking status, profession, familial ILD); co-morbidities; ILD management as analysed by the kind and frequency of pharmacological and non-pharmacological therapies; outcome; and consumption of resources will be recorded. Therefore, this registry will allow obtaining a comprehensive and current epidemiologic report for ILDs in Germany and can be particularly helpful in uncovering correlations between risk exposure and disease development.
This study, with up to 100 sites, initially focused on the federal states Baden-Wuerttemberg and Hesse, is planned for a minimum of 5 years and 600 patients should be enrolled as part of the study a screening/baseline visit, on which the Informed Consent Form will be signed, and every 6 months regularly updates/phone contacts will be performed.
Following quality procedures are applicable for this registry:
* Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.
* Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
* Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms, or interactive voice response systems).
* Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.
* Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.
* Plan for missing data to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results
* Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interstitial Lung Disease (ILD)
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Pneumology
Registry
EXCITING
Interstitial lung disease
ILD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
* Able to read and understand the scope and nature of data collection
* Aged ≥ 18 at time of informed consent
* Patients diagnosed with interstitial lung disease (ILD). Patients with suspicion on interstitial lung disease cannot be included into the registry, only after consens diagnosis of an ILD. This is also the case for patients with not classifiable ILDs.
Subjects with the following subtypes of ILD will be enrolled:
1. Idiopathic interstitial pneumonia (IIPs)
* Idiopathic pulmonary fibrosis (IPF)
* Non-specific interstitial pneumonia (NSIP)
* Desquamative interstitial pneumonia (DIP)
* Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
* Cryptogenic organizing pneumonia (COP)
* Lymphocytic interstitial pneumonia (LIP)
* Acute interstitial pneumonia (AIP)
* Rare forms of IIPs (e.g. pleuropulmonary fibroelastosis)
* Not classifiable IIP
2. Granulomatous lung disease
* Sarcoidosis
* Berylliosis
* Other (e.g. involvement in chronic inflammatory liver and gut diseases, except EAA)
3. Hypersensitivity pneumonitis (exogen allergic alveolitis (EAA))
* Farmer's lung
* Bird keepers' lung disease
* Origin unknown
* Other
4. Rheumatic and connective tissue diseases with pulmonary involvement like:
* Connective tissue disease (subtype)
* Vasculitis
* Rheumatoid arthritis
5. Pneumoconiosis
* Asbestosis
* Silicosis
* Other
6. Other forms
* Pulmonary lymphangioleiomyomatosis
* Pulmonary Langerhans' cell histiocytosis
* Pulmonary alveolar proteinosis
* Eosinophilic pneumonia
* Post-ARDS Fibrosis
7. Drug-related
8. Radiotherapy associated
9. Fibrosis in emphysema patients without signs of other ILDs (i.e. smoking related interstitial fibrosis or "emphysemasclerosis")
10. Others
11. Not classifiable
Furthermore for each subtype it will be queried, if a diagnosis of concomitant emphysema in ILD was made.
* Able to read and understand the scope and nature of data collection
* Aged ≥ 18 at time of informed consent
* Patients diagnosed with interstitial lung disease (ILD). Patients with suspicion on interstitial lung disease cannot be included into the registry, only after consens diagnosis of an ILD. This is also the case for patients with not classifiable ILDs.
Subjects with the following subtypes of ILD will be enrolled:
1. Idiopathic interstitial pneumonia (IIPs)
* Idiopathic pulmonary fibrosis (IPF)
* Non-specific interstitial pneumonia (NSIP)
* Desquamative interstitial pneumonia (DIP)
* Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
* Cryptogenic organizing pneumonia (COP)
* Lymphocytic interstitial pneumonia (LIP)
* Acute interstitial pneumonia (AIP)
* Rare forms of IIPs (e.g. pleuropulmonary fibroelastosis)
* Not classifiable IIP
2. Granulomatous lung disease
* Sarcoidosis
* Berylliosis
* Other (e.g. involvement in chronic inflammatory liver and gut diseases, except EAA)
3. Hypersensitivity pneumonitis (exogen allergic alveolitis (EAA))
* Farmer's lung
* Bird keepers' lung disease
* Origin unknown
* Other
4. Rheumatic and connective tissue diseases with pulmonary involvement like:
* Connective tissue disease (subtype)
* Vasculitis
* Rheumatoid arthritis
5. Pneumoconiosis
* Asbestosis
* Silicosis
* Other
6. Other forms
* Pulmonary lymphangioleiomyomatosis
* Pulmonary Langerhans' cell histiocytosis
* Pulmonary alveolar proteinosis
* Eosinophilic pneumonia
* Post-ARDS Fibrosis
7. Drug-related
8. Radiotherapy associated
9. Fibrosis in emphysema patients without signs of other ILDs (i.e. smoking related interstitial fibrosis or "emphysemasclerosis")
10. Others
11. Not classifiable
Furthermore for each subtype it will be queried, if a diagnosis of concomitant emphysema in ILD was made.
Exclusion Criteria
\- Patients without interstitial lung disease
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Giessen
OTHER
Sponsor Role
collaborator
German Center for Lung Research
OTHER
Sponsor Role
collaborator
Helmholtz Zentrum München
INDUSTRY
Sponsor Role
collaborator
Institut für Lungenforschung e.V.
UNKNOWN
Sponsor Role
collaborator
German Respiratory Society
OTHER
Sponsor Role
collaborator
WATL e.V.
UNKNOWN
Sponsor Role
collaborator
Bundesverband der Pneumologen
UNKNOWN
Sponsor Role
collaborator
Lungenfibrose e.V.
UNKNOWN
Sponsor Role
collaborator
Sacura GmbH
OTHER
Sponsor Role
collaborator
Syneed Medidata GmbH
INDUSTRY
Sponsor Role
collaborator
Heidelberg University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Kreuter
Head of Center for interstitial and rare lung diseases
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Kreuter, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Centre for interstitial and rare lung diseases, Pneumology and Respiratory Medicine, Thorax Clinic, University Hospital Heidelberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lungenärztliche Gemeinschaftspraxis Dr. Storz / Dr. Prettner
Böblingen, Baden-Wurttemberg, Germany
Site Status
Thoraxklinik Heidelberg, Abteilung Pneumologie und Beatmungsmedizin
Heidelberg, Baden-Wurttemberg, Germany
Site Status
Gesundheitsverbund Landeskreis Konstanz, Krankenhausbetriebsgesellschaft Konstanz
Konstanz, Baden-Wurttemberg, Germany
Site Status
Pneumologische Praxis im Zentrum - PiZ, Dr. med. Hans-Paul Eulenbruch und Dr. med. Alexander Rupp
Stuttgart, Baden-Wurttemberg, Germany
Site Status
Klinikum Stuttgart, Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie und Infektiologie, Pneumologie
Stuttgart, Baden-Wurttemberg, Germany
Site Status
Lungenpraxis Tübingen
Tübingen, Baden-Wurttemberg, Germany
Site Status
Pneumologisches Zentrum
Wiesloch, Baden-Wurttemberg, Germany
Site Status
Klinikverbund Kempten-Oberallgäu, Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin
Immenstadt im Allgäu, Bavaria, Germany
Site Status
Pneumologische Gemeinschaftspraxis Fulda Dres. Wiederhold, Schratz, Wissner
Fulda, Hesse, Germany
Site Status
Klinikum Fulda gAG, Medizinische Klinik V - Pneumologie
Fulda, Hesse, Germany
Site Status
Universitätsklinikum Gießen und Marburg GmbH, Medizinische Klinik und Poliklinik II
Giessen, Hesse, Germany
Site Status
Lungenfachklinik Immenhausen
Immenhausen, Hesse, Germany
Site Status
Universitätsklinikum Aachen, Medizinische Klinik I
Aachen, North Rhine-Westphalia, Germany
Site Status
Medizinisches Versorgungszentrum Malteser Bonn gem. GmbH, Malteser Lungen- und Allergiezentrum Bonn
Bonn, North Rhine-Westphalia, Germany
Site Status
St. Marien-Hospital GmbH
Cologne, North Rhine-Westphalia, Germany
Site Status
Malteser Krankenhaus St. Hildegardis, Klinik für Pneumologie und Beatmungsmedizin
Cologne, North Rhine-Westphalia, Germany
Site Status
Johanniter-Krankenhaus Rheinhausen GmbH
Duisburg, North Rhine-Westphalia, Germany
Site Status
Ruhrlandklinik - Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, North Rhine-Westphalia, Germany
Site Status
Klinkum Gütersloh, Medizinische Klink III, Pneumologie, Schlaf- und Beatmungsmedizin, Infektiologie und Allgemeine Innere Medizin
Gütersloh, North Rhine-Westphalia, Germany
Site Status
Katholische Kranken- und Pflegeeinrichtung Leverkusen GmbH, St. Remigius Krankenhaus Opladen
Leverkusen, North Rhine-Westphalia, Germany
Site Status
framol-med GmbH, Pneumoglische Gemeinschaftspraxis Rheine
Rheine, North Rhine-Westphalia, Germany
Site Status
Krankenhaus Bethanien gGmbH, Klinik für Pneumologie und Allergologie, Zentrum für Schlaf- und Beatmungsmedizin
Solingen, North Rhine-Westphalia, Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Germany
References
Explore related publications, articles, or registry entries linked to this study.
Demedts M, Wells AU, Anto JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Dalphin JC, Taylor AN. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001 Sep;32:2s-16s.
Reference Type
BACKGROUND
Akgun KM, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012 Mar;67(3):276-91. doi: 10.1093/gerona/glr251. Epub 2012 Feb 15.
Reference Type
BACKGROUND
Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol. 2012;2012:415272. doi: 10.5402/2012/415272. Epub 2012 Mar 27.
Reference Type
BACKGROUND
Gunnarsson R, Aalokken TM, Molberg O, Lund MB, Mynarek GK, Lexberg AS, Time K, Dhainaut AS, Bertelsen LT, Palm O, Irgens K, Becker-Merok A, Nordeide JL, Johnsen V, Pedersen S, Proven A, Garabet LS, Gran JT. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012 Dec;71(12):1966-72. doi: 10.1136/annrheumdis-2011-201253. Epub 2012 May 1.
Reference Type
BACKGROUND
Hallowell RW, Reed RM, Fraig M, Horton MR, Girgis RE. Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. Pulm Circ. 2012 Jan-Mar;2(1):101-6. doi: 10.4103/2045-8932.94842.
Reference Type
BACKGROUND
Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol. 2012 Mar;5(2):219-27. doi: 10.1586/ecp.12.9.
Reference Type
BACKGROUND
Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637. doi: 10.1155/2012/143637. Epub 2012 May 10.
Reference Type
BACKGROUND
Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology. 2012 Jul;17(5):861-8. doi: 10.1111/j.1440-1843.2012.02187.x.
Reference Type
BACKGROUND
King TE Jr. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10;364(10):968-70. doi: 10.1056/NEJMe1013966. No abstract available.
Reference Type
BACKGROUND
Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med. 2009 Sep 1;180(5):407-14. doi: 10.1164/rccm.200812-1966OC. Epub 2009 Jun 19.
Reference Type
BACKGROUND
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
Reference Type
BACKGROUND
Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1147-53. doi: 10.1164/rccm.201108-1420PP. Epub 2012 Feb 23.
Reference Type
BACKGROUND
Lynge E. Implication for epidemiology of disease registers. Public Health Rev. 1993-1994;21(3-4):263-70.
Reference Type
BACKGROUND
American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. doi: 10.1164/ajrccm.165.2.ats01. No abstract available.
Reference Type
BACKGROUND
Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002 May;19(5):794-6. doi: 10.1183/09031936.02.00492002. No abstract available.
Reference Type
BACKGROUND
Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D, Mall M, Gunther A, Markart P. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry--The EXCITING-ILD Registry. Biomed Res Int. 2015;2015:123876. doi: 10.1155/2015/123876. Epub 2015 Nov 10.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILD Patient Registry
Identifier Type: -
Identifier Source: org_study_id